Make the Diagnosis: Spring 2021
Apr 21, 2021
A bright 16-year-old high school freshman overdue for a well visit turns a 5-minute encounter into a 2-hour holistic visit.
The transport team includes nurses, medics, emergency medical technicians (EMTs), respiratory therapists, physicians, intake clinicians, equipment techs and communication specialists. Each team member has a different skill set and plays a vital role.
Apr 21, 2021
A bright 16-year-old high school freshman overdue for a well visit turns a 5-minute encounter into a 2-hour holistic visit.
Apr 20, 2021
Grant awarded to CHOP and collaborating institutions will fund research into identifying and treating slowly progressive neuroblastoma, which currently lacks treatment options.
Apr 20, 2021
Specialized driving instructors say path to getting licensed for autistic teens may be longer, but achievable with tailored instruction and other support.
Apr 19, 2021
CHOP researchers found a simple assay using a blood sample could identify EoE milk allergy with accuracy and sensitivity.
Apr 16, 2021
The Cardiac Center held its annual Innovation Day, where six innovative proposals were presented. Each project aims at enhancing the patient/family experience.
Apr 19, 2021
CHOP has appointed Sophia G. Holder as Executive Vice President and Chief Financial Officer. In joining the CHOP leadership team, Sophia brings more than 20 years of experience in the healthcare industry, most recently serving as the Vice President of Finance at Boston Children’s Hospital.
Apr 15, 2021
In light the ongoing challenges, it is so important to celebrate our colleagues. This edition, as I think of our CHOP Alumni Motto: Keep … Tradition, Keep … in Mind and Keep … in Touch!
Apr 15, 2021
News updates from the Spring 20201 edition of Children's Doctor.
Apr 15, 2021
A recent CHOP study found that newly licensed drivers on the autism spectrum have similar—or even lower—per-driver rates of crash involvement than their non-autistic peers.
Apr 15, 2021
CHOP researchers have identified BAFF as a key target that may be responsible for treatment failure in about 30% of patients with hemophilia A.